Okechukwu Mgbemena, MD
Cardiovascular Disease · Kingwood, TXNPI 1750709895
Payments from drug & device makers
Across 144 payments — averaging $125.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$5K
- Edwards Lifesciences$4K
- Angiodynamics, Inc.$3K
- Abbott$2K
- W. L. Gore & Associates, Inc.$2K
- Medtronic$2K
- plus $830 from 8 others
What the payments were for
- Travel & lodging$11,51463%
- Food & beverage$6,04833%
- Education$5773%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 24 | $4,611 |
| Edwards Lifesciences | 48 | $4,487 |
| Angiodynamics, Inc. | 10 | $2,530 |
| Abbott | 16 | $2,101 |
| W. L. Gore & Associates, Inc. | 17 | $2,046 |
| Medtronic | 10 | $1,534 |
| Cook Medical LLC | 5 | $238 |
| Inari Medical, Inc. | 1 | $155 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $132 |
| Kestra Medical Technology Services, Inc. | 1 | $102 |
| Novo Nordisk | 1 | $67 |
| Abiomed | 1 | $61 |
| Shockwave Medical, Inc | 2 | $43 |
| Amgen | 2 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AngioVac$2,370
- GENERAL VASCULAR ACCESS$2,025
- VersaCross Access Solution$1,980
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,265
- OPTIS$1,136
- GORE CARDIOFORM Septal Occluder$996
- COREVALVE EVOLUT R$853
- SAPIEN 3 Ultra RESILIA$722
- GORE CARDIOFORM ASD Occluder$669
- ENSITE$237
- EMBOSHIELD NAV6$170
- ONYX FRONTIER$164
- HawkOne$159
- CT THROMBECTOMY SYSTEM KIT$155
- FLOWTRIEVER CATHETER, S$155
- Zilver PTX$148
- CARDIOMEMS$147
- Assure WCD$102
How this compares
$18,139 in reported general payments places this provider in the 75th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $13,987 |
| ClopidogrelClopidogrel Bisulfate | 109 | $1,732 |
| Metoprolol Succinate | 14 | $313 |
| Prasugrel Hcl | 12 | $308 |
| Atorvastatin Calcium | 19 | $217 |
| Amlodipine Besylate | 15 | $163 |
| Losartan Potassium | 14 | $159 |
| Ezetimibe | 12 | $133 |
| Rosuvastatin Calcium | 11 | $112 |
| Carvedilol | 11 | $94 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 13 | $32 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Kingwood
- Robert SalazarKingwood$572K
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.